The results of their study appear in The Lancet. The researchers have adapted the 8cm long trachoma dipstick test on the "FirstBurst" test, which became so successful in detecting the sexually transmitted form of Chlamydia. Dr Helen Lee of the Cambridge University led the both studies.
"The test is an important advance in the fight against trachoma. At present, the amount of azithromycin pledged by the manufacturer, Pfizer, will not be sufficient to treat everyone living in endemic communities. Yet, much of the drug is wasted in treating communities which no longer need it," said Professor Mabey, from the London School of Hygiene and Tropical Medicine. "The new test will enable programme managers to find out for themselves which communities still harbor the infection and thus to focus treatment on the communities which really need it."
The World Health Organization says that 84 million people in 55 countries are potentially in need of treatment for trachoma.